You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR VORAPAXAR SULFATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for vorapaxar sulfate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02475837 ↗ Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access Completed Merck Sharp & Dohme Corp. Phase 2 2015-08-26 The Objectives of this study are: 1. To determine if vorapaxar safely improves arteriovenous (AV) fistula functional maturation when administered during the maturation process compared with placebo. 2. To determine if vorapaxar safely improves AV fistula patency, allowing for secondary procedures to aid in fistula maturation compared with placebo. 3. To determine if vorapaxar safely facilitates successful cannulation of AV fistulas for hemodialysis compared with placebo. This is a randomized placebo-controlled double-blind pilot trial. Study procedures will be conducted at Stanford University Medical Center, and standard-of-care (SOC) procedures will be conducted at Stanford and it's affiliated hospitals (Veteran's Affairs Palo Alto Health Care System and the Stanford Vascular Surgery Clinic at Valley Medical Center). The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm).
NCT02475837 ↗ Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access Completed Ken Mahaffey Phase 2 2015-08-26 The Objectives of this study are: 1. To determine if vorapaxar safely improves arteriovenous (AV) fistula functional maturation when administered during the maturation process compared with placebo. 2. To determine if vorapaxar safely improves AV fistula patency, allowing for secondary procedures to aid in fistula maturation compared with placebo. 3. To determine if vorapaxar safely facilitates successful cannulation of AV fistulas for hemodialysis compared with placebo. This is a randomized placebo-controlled double-blind pilot trial. Study procedures will be conducted at Stanford University Medical Center, and standard-of-care (SOC) procedures will be conducted at Stanford and it's affiliated hospitals (Veteran's Affairs Palo Alto Health Care System and the Stanford Vascular Surgery Clinic at Valley Medical Center). The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm).
NCT02475837 ↗ Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access Completed Matthew Mell Phase 2 2015-08-26 The Objectives of this study are: 1. To determine if vorapaxar safely improves arteriovenous (AV) fistula functional maturation when administered during the maturation process compared with placebo. 2. To determine if vorapaxar safely improves AV fistula patency, allowing for secondary procedures to aid in fistula maturation compared with placebo. 3. To determine if vorapaxar safely facilitates successful cannulation of AV fistulas for hemodialysis compared with placebo. This is a randomized placebo-controlled double-blind pilot trial. Study procedures will be conducted at Stanford University Medical Center, and standard-of-care (SOC) procedures will be conducted at Stanford and it's affiliated hospitals (Veteran's Affairs Palo Alto Health Care System and the Stanford Vascular Surgery Clinic at Valley Medical Center). The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for vorapaxar sulfate

Condition Name

Condition Name for vorapaxar sulfate
Intervention Trials
AV Fistula 1
Fistula 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for vorapaxar sulfate
Intervention Trials
Fistula 1
Arteriovenous Fistula 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for vorapaxar sulfate

Trials by Country

Trials by Country for vorapaxar sulfate
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for vorapaxar sulfate
Location Trials
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for vorapaxar sulfate

Clinical Trial Phase

Clinical Trial Phase for vorapaxar sulfate
Clinical Trial Phase Trials
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for vorapaxar sulfate
Clinical Trial Phase Trials
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for vorapaxar sulfate

Sponsor Name

Sponsor Name for vorapaxar sulfate
Sponsor Trials
Merck Sharp & Dohme Corp. 1
Ken Mahaffey 1
Matthew Mell 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for vorapaxar sulfate
Sponsor Trials
Other 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.